Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HART plus cetuximab plus weekly cisplatin for unresectable locally advanced head and neck squamous cell carcinoma
ISRCTN47339346Phase 2Completed
- Sponsor
- Martin-Luther-University Halle-Wittenberg (Germany)
- Start
- Jun 2005
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of cetuximab and cisplatin in head and neck squamous cell carcinoma (HNSCC) (5 arms), sponsored by Martin-Luther-University Halle-Wittenberg (Germany). Primary endpoints: Maximum tolerated dose of cisplatin and Two-year progression-free survival. Started Jun 2005; status: completed.
02
Drugs
cetuximabcisplatin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ISRCTN47339346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN47339346.